A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE -/- mouse model

Abstract

The glucagon like peptide-1 receptor (GLP-1R) agonist liraglutide attenuates induction of plasminogen activator inhibitor type-1 (PAI-1) and vascular adhesion molecule (VAM) expression in human vascular endothelial cells (hVECs) in vitro and may afford protection against endothelial cell dysfunction (ECD), an early abnormality in diabetic vascular disease. Our study aimed to establish the dependence of the in vitro effects of liraglutide on the GLP-1R and characterise its in vivo effects in a mouse model of ECD. In vitro studies utilised the human vascular endothelial cell line C11-STH and enzyme-linked immunosorbent assays (ELISA) for determination of PAI-1 and VAM expression. In vivo studies of vascular reactivity and immunohistochemical analysis were performed in the ApoE^-/- mouse model. In vitro studies demonstrated GLP-1R-dependent liraglutide-mediated inhibition of stimulated PAI-1 and VAM expression. In vivo studies demonstrated significant improvement in endothelial function in liraglutide treated mice, a GLP-1R dependent effect. Liraglutide treatment also increased endothelial nitric oxide synthase (eNOS) and reduced intercellular adhesion molecule-1 (ICAM-1) expression in aortic endothelium, an effect again dependent on the GLP-1R. Together these studies identify in vivo protection, by the GLP-1R agonist liraglutide, against ECD and provide a potential molecular mechanism responsible for these effects.

Keywords

Endothelium GLP-1 incretin liraglutide NFκB

References

Hobb FD Type-2 diabetes mellitus related cardiovascular risk: new options for interventions to reduce risk and treatment goals. Atherosclerosis 2006; 7: 29-32.

Vanhoutte PM Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009; 73: 595-601.

Morigi M. , Angioletti S. , Imberti B. , et al. Leukocyte- endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NFkB-dependent fashion. J Clin Invest 1998; 101: 1905-1915.

Liu HB , Hu YS , Medcalf RL , Simpson RW and Dear AE Thiazolidinediones inhibit TNF alpha induction of PAI-1 independent of PPARgamma activation. Biochem Biophys Res Commun 2005 ; 334: 30-37.

Liu HB , Hu YS , Simpson RW and Dear AE Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen activator inhibitor-1 expression. J Endocrinol 2008; 196: 57-65.

Norata GD , Tibolla G. , Seccomandi PM , Poletti A. and Catapano AL Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab 2006; 91: 546-554.

Kumar S. , Sharma A. , Madan B. , Singhal V. and Ghosh B. Isoliquiritigenin inhibits IkB kinase activity and ROS generation to block TNF-alpha induced expression of cell adhesion molecules on human endothelial cells. Biochem Pharmacol 2007; 73: 1602-1612.

Iwasaki H. , Okamoto R. , Kato S. , et al High glucose induces plasminogen activator inhibitor-1 expression through Rho/ Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis 2008; 196: 22-28.

Kim W. and Egan JM The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512.

10.

Drab SR Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010; 30: 609-624.

11.

Nyström T. , Gutniak MK , Zhang Q. , et al. Effects of glucagon like peptide on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004 ; 287: E1209-E1215.

12.

Golpon HA , Puechner A. , Welte T. , Wichert PV and Feddersen CO Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001; 102: 81-86.

13.

Yu M. , Moreno C. , Hoagland KM , et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl saltsensitive rats. J Hypertens 2003; 21: 1125-1135.

14.

Elbrønd B. , Jakobsen G. , Larsen S. , et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25: 1398- 1404.

15.

Juhl CB , Hollingdal M. , Sturis J. , et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes . Diabetes 2002; 51: 424-429.

16.

Degn KB , Juhl CB , Sturis J. , et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004 ; 53: 1187-1194.

17.

Vilsböll T. , Zdravkovic M. , Le-Thi T. , et al. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care 2007; 30: 1608-1610.

18.

Courrèges JP , Vilsbøll T. , Zdravkovic M. , et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008; 25: 1129-1131.

19.

Liu HB , Dear AE , Knudsen LB and Simpson RW A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009; 201: 59-66.

20.

Cockerill GW , Meyer G. , Noack L. , Vadas MA and Gamble JR Characterization of a spontaneously transformed human endothelial cell line . Lab Invest 1994; 71: 497-509.

21.

Rolin B. , Larsen MO , Gotfredsen CF , et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 83: E745-E752.

22.

De León DD , Li C. , Delson MI , Matschinsky FM , Stanley CA and Stoffers DA Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion. J Biol Chem 2008; 283: 25786-25793.

23.

Vinh A. , Widdop RE , Drummond GR and Gaspari TA Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res 2008; 77: 178-187.

24.

Blankenberg S. , Barbaux S. and Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.

25.

Hattori Y. , Jojima T. , Tomizawa A. , et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010; 53: 2256-2263.

26.

Trottein F. , Nutten S. , Angeli V. , et al. Schistosoma mansoni schistosomula reduce E-selectin and VCAM-1 expression in TNF-alpha-stimulated lung microvascular endothelial cells by interfering with the NF-kappaB pathway. Eur J Immunol 1999; 29: 3691-3701.

27.

Kang JH , Chang SY , Jang HJ , et al. Exendin-4 inhibits interleukin-1beta-induced iNOS expression at the protein level, but not at the transcriptional and posttranscriptional levels, in RINm5F beta-cells. J Endocrinol 2009; 202: 65-75.

28.

Arakawa M. , Mita T. , Azuma K. , et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4 . Diabetes 2010; 59: 1030-1037.

29.

Ten RM , Paya CV and Israël N. The characterization of the promoter of the gene encoding the p50 subunit of NF-kappa B indicates that it participates in its own regulation. EMBO J 1992; 11: 195-203.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.33 MB